Asterias Biotherapeutics Inc (AST) Receives “Buy” Rating from HC Wainwright

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Wednesday.

Other analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Tuesday, October 10th. ValuEngine downgraded shares of Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 4th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Asterias Biotherapeutics has a consensus rating of “Buy” and an average target price of $9.19.

Shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) opened at $2.55 on Wednesday. Asterias Biotherapeutics has a fifty-two week low of $2.00 and a fifty-two week high of $5.70.

COPYRIGHT VIOLATION NOTICE: “Asterias Biotherapeutics Inc (AST) Receives “Buy” Rating from HC Wainwright” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

What are top analysts saying about Asterias Biotherapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Asterias Biotherapeutics Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit